Remove Big Data Remove Licensing Remove Life Science
article thumbnail

Rare diseases, repurposing and the role of AI

pharmaphorum

These might be licensed drugs that could hold potential for a patent extension, or drugs which failed efficacy trials for an intended indication. In the quest to repurpose a drug for a rare condition, there is a need to look at any and all available data. The post Rare diseases, repurposing and the role of AI appeared first on.

Trials 105
article thumbnail

PMN Innovation Summit 2021

Pharma Marketing Network

Licensed Clinical Psychologist, Clinical Director, Virtual Counselor/College Telehealth. Recent shifts in rep access, HCP media preferences and the emergence of new data-driven platforms have forced pharmaceutical and life science organizations to accelerate their digital transformation. Reena Kolar , Ph.D,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PMN Innovation Summit 2021

Pharma Marketing Network

Licensed Clinical Psychologist, Clinical Director, Virtual Counselor/College Telehealth. Recent shifts in rep access, HCP media preferences and the emergence of new data-driven platforms have forced pharmaceutical and life science organizations to accelerate their digital transformation. Reena Kolar , Ph.D,

article thumbnail

A history of AstraZeneca

pharmaphorum

Meanwhile, the search for the ‘right target’ led the company to collaborate with Cancer Research UK and launch the Functional Genomics Centre , a centre of excellence for genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines, including those based on CRISPR technology.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. In 2022, the FDA proceeded to grant official licensing for Moderna’s Spikevax COVID-19 vaccine.

Sales 98